132 related articles for article (PubMed ID: 35322192)
21. Diagnostic utility of LMO2 immunohistochemistry in distinguishing T-lymphoblastic leukemia/lymphoma from thymoma.
Bansal D; Pasricha S; Gupta G; Sharma A; Durga G; Kamboj M; Mehta A
Indian J Pathol Microbiol; 2024; 67(1):141-144. PubMed ID: 38358204
[TBL] [Abstract][Full Text] [Related]
22. Overexpression of Lmo2 initiates T-lymphoblastic leukemia via impaired thymocyte competition.
Abdulla HD; Alserihi R; Flensburg C; Abeysekera W; Luo MX; Gray DHD; Liu X; Smyth GK; Alexander WS; Majewski IJ; McCormack MP
J Exp Med; 2023 Jun; 220(6):. PubMed ID: 36920307
[TBL] [Abstract][Full Text] [Related]
23. LMO2 Is a Specific Marker of T-Lymphoblastic Leukemia/Lymphoma.
Jevremovic D; Roden AC; Ketterling RP; Kurtin PJ; McPhail ED
Am J Clin Pathol; 2016 Feb; 145(2):180-90. PubMed ID: 26796495
[TBL] [Abstract][Full Text] [Related]
24. Functional interactions between Lmo2, the Arf tumor suppressor, and Notch1 in murine T-cell malignancies.
Treanor LM; Volanakis EJ; Zhou S; Lu T; Sherr CJ; Sorrentino BP
Blood; 2011 May; 117(20):5453-62. PubMed ID: 21427293
[TBL] [Abstract][Full Text] [Related]
25. LMO2 Confers Synthetic Lethality to PARP Inhibition in DLBCL.
Parvin S; Ramirez-Labrada A; Aumann S; Lu X; Weich N; Santiago G; Cortizas EM; Sharabi E; Zhang Y; Sanchez-Garcia I; Gentles AJ; Roberts E; Bilbao-Cortes D; Vega F; Chapman JR; Verdun RE; Lossos IS
Cancer Cell; 2019 Sep; 36(3):237-249.e6. PubMed ID: 31447348
[TBL] [Abstract][Full Text] [Related]
26. Diagnostic Utility of the Germinal Center-associated Markers GCET1, HGAL, and LMO2 in Hematolymphoid Neoplasms.
Menter T; Gasser A; Juskevicius D; Dirnhofer S; Tzankov A
Appl Immunohistochem Mol Morphol; 2015 Aug; 23(7):491-8. PubMed ID: 25203428
[TBL] [Abstract][Full Text] [Related]
27. A DNA-binding mutant of TAL1 cooperates with LMO2 to cause T cell leukemia in mice.
Draheim KM; Hermance N; Yang Y; Arous E; Calvo J; Kelliher MA
Oncogene; 2011 Mar; 30(10):1252-60. PubMed ID: 21057528
[TBL] [Abstract][Full Text] [Related]
28. A previously unrecognized promoter of LMO2 forms part of a transcriptional regulatory circuit mediating LMO2 expression in a subset of T-acute lymphoblastic leukaemia patients.
Oram SH; Thoms JA; Pridans C; Janes ME; Kinston SJ; Anand S; Landry JR; Lock RB; Jayaraman PS; Huntly BJ; Pimanda JE; Göttgens B
Oncogene; 2010 Oct; 29(43):5796-808. PubMed ID: 20676125
[TBL] [Abstract][Full Text] [Related]
29. Identification of LMO2 transcriptome and interactome in diffuse large B-cell lymphoma.
Cubedo E; Gentles AJ; Huang C; Natkunam Y; Bhatt S; Lu X; Jiang X; Romero-Camarero I; Freud A; Zhao S; Bacchi CE; Martínez-Climent JA; Sánchez-García I; Melnick A; Lossos IS
Blood; 2012 Jun; 119(23):5478-91. PubMed ID: 22517897
[TBL] [Abstract][Full Text] [Related]
30. Lmo2 expression defines tumor cell identity during T-cell leukemogenesis.
García-Ramírez I; Bhatia S; Rodríguez-Hernández G; González-Herrero I; Walter C; González de Tena-Dávila S; Parvin S; Haas O; Woessmann W; Stanulla M; Schrappe M; Dugas M; Natkunam Y; Orfao A; Domínguez V; Pintado B; Blanco O; Alonso-López D; De Las Rivas J; Martín-Lorenzo A; Jiménez R; García Criado FJ; García Cenador MB; Lossos IS; Vicente-Dueñas C; Borkhardt A; Hauer J; Sánchez-García I
EMBO J; 2018 Jul; 37(14):. PubMed ID: 29880602
[TBL] [Abstract][Full Text] [Related]
31. Detection of LIM domain only 2 (LMO2) in normal human tissues and haematopoietic and non-haematopoietic tumours using a newly developed rabbit monoclonal antibody.
Agostinelli C; Paterson JC; Gupta R; Righi S; Sandri F; Piccaluga PP; Bacci F; Sabattini E; Pileri SA; Marafioti T
Histopathology; 2012 Jul; 61(1):33-46. PubMed ID: 22394247
[TBL] [Abstract][Full Text] [Related]
32. [Expression of microRNA-223 in lymphocytic leukemia cells and its action mechanism].
Nan Z; Liang Y; Fu R; Liu H; Ruan EB; Wang XM; Wang GJ; Qu W; Liu H; Wu YH; Song J; Xing LM; Guan J; Li LJ; Wang HQ; Shao ZH
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Jun; 21(3):556-61. PubMed ID: 23815897
[TBL] [Abstract][Full Text] [Related]
33. Interleukin-7 receptor mutants initiate early T cell precursor leukemia in murine thymocyte progenitors with multipotent potential.
Treanor LM; Zhou S; Janke L; Churchman ML; Ma Z; Lu T; Chen SC; Mullighan CG; Sorrentino BP
J Exp Med; 2014 Apr; 211(4):701-13. PubMed ID: 24687960
[TBL] [Abstract][Full Text] [Related]
34. Notch1 inhibition targets the leukemia-initiating cells in a Tal1/Lmo2 mouse model of T-ALL.
Tatarek J; Cullion K; Ashworth T; Gerstein R; Aster JC; Kelliher MA
Blood; 2011 Aug; 118(6):1579-90. PubMed ID: 21670468
[TBL] [Abstract][Full Text] [Related]
35. LMO2 (LIM domain only 2) is expressed in a subset of acute myeloid leukaemia and correlates with normal karyotype.
Patel JL; Pournazari P; Haggstrom SJ; Kosari F; Shabani-Rad MT; Natkunam Y; Mansoor A
Histopathology; 2014 Jan; 64(2):226-33. PubMed ID: 24330148
[TBL] [Abstract][Full Text] [Related]
36. ERG promotes T-acute lymphoblastic leukemia and is transcriptionally regulated in leukemic cells by a stem cell enhancer.
Thoms JA; Birger Y; Foster S; Knezevic K; Kirschenbaum Y; Chandrakanthan V; Jonquieres G; Spensberger D; Wong JW; Oram SH; Kinston SJ; Groner Y; Lock R; MacKenzie KL; Göttgens B; Izraeli S; Pimanda JE
Blood; 2011 Jun; 117(26):7079-89. PubMed ID: 21536859
[TBL] [Abstract][Full Text] [Related]
37. The expression of LMO2 protein in acute B-cell and myeloid leukemia.
Cobanoglu U; Sonmez M; Ozbas HM; Erkut N; Can G
Hematology; 2010 Jun; 15(3):132-4. PubMed ID: 20557670
[TBL] [Abstract][Full Text] [Related]
38. Targeting LMO2 with a peptide aptamer establishes a necessary function in overt T-cell neoplasia.
Appert A; Nam CH; Lobato N; Priego E; Miguel RN; Blundell T; Drynan L; Sewell H; Tanaka T; Rabbitts T
Cancer Res; 2009 Jun; 69(11):4784-90. PubMed ID: 19487290
[TBL] [Abstract][Full Text] [Related]
39. Enforced expression of E47 has differential effects on Lmo2-induced T-cell leukemias.
Goodings C; Tripathi R; Cleveland SM; Elliott N; Guo Y; Shyr Y; Davé UP
Leuk Res; 2015 Jan; 39(1):100-9. PubMed ID: 25499232
[TBL] [Abstract][Full Text] [Related]
40. LMO2-negative Expression Predicts the Presence of MYC Translocations in Aggressive B-Cell Lymphomas.
Colomo L; Vazquez I; Papaleo N; Espinet B; Ferrer A; Franco C; Comerma L; Hernandez S; Calvo X; Salar A; Climent F; Mate JL; Forcada P; Mozos A; Nonell L; Martinez A; Carrio A; Costa D; Dlouhy I; Salaverria I; Martin-Subero JI; Lopez-Guillermo A; Valera A; Campo E;
Am J Surg Pathol; 2017 Jul; 41(7):877-886. PubMed ID: 28288039
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
